IMS Reports AbbVie (ABBV) Viekira Pak Week 1 Scripts (GILD)

Gilead Sciences (NASDAQ: GILD) week 11 Harvoni TRx was 5381, down 17% week-over-week, according to RBC Capital citing IMS. Harvoni NRx was 2500, a decline of 26%. Harvoni+Sovaldi TRx was 7402, and NRx was 3177.

AbbVie (NYSE: ABBV) Viekira Pak week 1 TRx was 14.

Commenting, analyst Michael J. Yee of RBC said, "This is far lower compared to Sovaldi week 1 NRx of 151 (in midDecember) and Harvoni week 1 NRx of 444 (in mid-October). Viekira Pak's week 1 launch is comparable to JNJ (NYSE: JNJ) Olysio week 1 NRx of 10; VRTX Incivek week 1 NRx of 14."

"As we've written in previous notes, we expect ABBV to gain low-single-digit share of NRx and pick up towards ~5-10% over time through Q1:15. GILD's Harvoni and ABBV's Viekira Pak are only competing within the 70-75% GT1 patients, as GILD's Sovaldi is the only approved regimen for GT2,3 patients," he added.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Everpure (P) PT Raised to $128 at Northland
• Trump says to rename Lake Ontario to Lake America